uniQure(US:QURE) TMX Newsfile·2026-02-26 14:21Core Viewpoint - A class action lawsuit has been filed against uniQure N.V. for allegedly misleading investors regarding the effectiveness of its gene therapy candidate AMT-130 and the likelihood of FDA approval [1][3]. Company Overview - uniQure N.V. is based in Amsterdam and focuses on developing and commercializing gene therapies for severe diseases, particularly Huntington's disease and other neurological disorders [2]. Legal Proceedings - The lawsuit pertains to investors who acquired uniQure securities between September 24, 2025, and October 31, 2025, with a deadline of April 13, 2026, for potential lead plaintiff appointments [2]. - The complaint claims that uniQure misrepresented the status of FDA agreement on study endpoints, which led to a significant stock price increase of nearly 250%, from $13.66 to $47.50 per share, following positive statements [3]. - On November 3, 2025, it was revealed that the FDA agreement on study design was not finalized, causing a stock price drop of over 49%, from $67.69 to $34.29 per share [4].